OVERVIEW

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

More>>
  • May 10, 2019

    GAITHERSBURG, Md. , May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between Novavax and The Bank of New York Mellon Trust...More>>

  • May 08, 2019

    GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of...More>>

  • May 02, 2019

                 Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , May 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2019 ....More>>

Stock Quote